Lantheus (NASDAQ:LNTH) Issues FY24 Earnings Guidance

Lantheus (NASDAQ:LNTH) issued an update on its FY24 earnings guidance on Wednesday morning. The company provided EPS guidance of $6.60-6.70 for the period, compared to the consensus EPS estimate of $7.07. The company issued revenue guidance of $1.50-1.52 billion, compared to the consensus revenue estimate of $1.52 billion. Lantheus also updated its FY 2024 guidance to 6.600-6.700 EPS.

Lantheus Price Performance

Lantheus stock opened at $109.77 on Wednesday. Lantheus has a one year low of $50.20 and a one year high of $126.89. The business has a fifty day moving average price of $90.93 and a 200-day moving average price of $72.42. The company has a debt-to-equity ratio of 0.59, a current ratio of 4.84 and a quick ratio of 4.55. The firm has a market capitalization of $7.61 billion, a P/E ratio of 16.76 and a beta of 0.51.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings data on Thursday, May 2nd. The medical equipment provider reported $1.51 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.40 by $0.11. Lantheus had a return on equity of 54.10% and a net margin of 33.72%. The company had revenue of $369.98 million for the quarter, compared to the consensus estimate of $349.46 million. As a group, equities research analysts forecast that Lantheus will post 6.46 EPS for the current year.

Wall Street Analyst Weigh In

LNTH has been the topic of several analyst reports. Mizuho lifted their price objective on Lantheus from $90.00 to $100.00 and gave the stock a buy rating in a report on Friday, May 3rd. B. Riley raised their target price on Lantheus from $105.00 to $146.00 and gave the stock a buy rating in a research note on Thursday, July 25th. SVB Leerink raised their target price on Lantheus from $106.00 to $127.00 and gave the stock an outperform rating in a research note on Thursday, July 11th. Truist Financial raised their target price on Lantheus from $96.00 to $141.00 and gave the stock a buy rating in a research note on Thursday, July 11th. Finally, StockNews.com cut Lantheus from a buy rating to a hold rating in a research note on Friday, May 3rd. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of Moderate Buy and an average price target of $120.57.

Insider Activity at Lantheus

In related news, insider Daniel Niedzwiecki sold 12,873 shares of the company’s stock in a transaction that occurred on Thursday, May 30th. The stock was sold at an average price of $79.86, for a total value of $1,028,037.78. Following the transaction, the insider now directly owns 80,244 shares of the company’s stock, valued at approximately $6,408,285.84. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, insider Daniel Niedzwiecki sold 12,873 shares of the stock in a transaction on Thursday, May 30th. The stock was sold at an average price of $79.86, for a total transaction of $1,028,037.78. Following the transaction, the insider now directly owns 80,244 shares of the company’s stock, valued at approximately $6,408,285.84. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CAO Andrea Sabens sold 341 shares of the stock in a transaction on Monday, May 13th. The shares were sold at an average price of $76.89, for a total value of $26,219.49. Following the transaction, the chief accounting officer now directly owns 62,898 shares in the company, valued at $4,836,227.22. The disclosure for this sale can be found here. In the last three months, insiders have sold 44,799 shares of company stock valued at $3,769,262. 1.50% of the stock is owned by corporate insiders.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.